Get the Stockscreener App
35.95
7.54%
2.5405
Scholar Rock Holding Corp stock is traded at $35.95, with a volume of 749.45K.
It is up +7.54% in the last 24 hours and up +19.77% over the past month.
Scholar Rock Holding Corp is a late-stage biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for treating serious diseases in which signaling by protein growth factors plays a fundamental role. Its pipeline includes Neuromuscular and Obesity, Immuno-oncology, Fibrotic Disease, and Hematology. The group operates and manages its business as a single segment to assess performance and make operating decisions.
See More
Previous Close:
$33.41
Open:
$34.67
24h Volume:
749.45K
Relative Volume:
0.58
Market Cap:
$3.27B
Revenue:
$47.30M
Net Income/Loss:
$-225.97M
P/E Ratio:
-15.30
EPS:
-2.35
Net Cash Flow:
$-188.86M
1W Performance:
-1.07%
1M Performance:
+19.77%
6M Performance:
-21.14%
1Y Performance:
+345.23%
1-Day Range:
$33.31
$36.24
1-Week Range:
$31.62
$36.90
52-Week Range:
$6.76
$46.98
Scholar Rock Holding Corp Stock (SRRK) Company Profile
Name
Scholar Rock Holding Corp
Sector
Industry
Phone
857-259-3860
Address
301 BINNEY STREET, CAMBRIDGE, MA
Compare SRRK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SRRK
Scholar Rock Holding Corp
|
35.93 | 3.27B | 47.30M | -225.97M | -188.86M | -2.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
443.99 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
518.01 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
323.81 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
563.44 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
268.76 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Scholar Rock Holding Corp Stock (SRRK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-26-24 | Reiterated | H.C. Wainwright | Buy |
| Oct-07-24 | Reiterated | H.C. Wainwright | Buy |
| Mar-28-24 | Initiated | Raymond James | Strong Buy |
| Oct-25-23 | Upgrade | Jefferies | Hold → Buy |
| Apr-03-23 | Resumed | Piper Sandler | Overweight |
| Sep-19-22 | Resumed | H.C. Wainwright | Buy |
| Jul-12-22 | Initiated | Truist | Buy |
| Mar-23-22 | Initiated | H.C. Wainwright | Buy |
| Dec-22-21 | Downgrade | Jefferies | Buy → Hold |
| Nov-19-21 | Initiated | Piper Sandler | Overweight |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Jan-11-21 | Initiated | Credit Suisse | Outperform |
| Jan-06-21 | Initiated | JP Morgan | Overweight |
| Mar-12-20 | Initiated | Robert W. Baird | Outperform |
View All
Scholar Rock Holding Corp Stock (SRRK) Latest News
Scholar Rock (NASDAQ:SRRK) Receives Outperform Rating from Wedbush - MarketBeat
Why Scholar Rock Shares Are Soaring Today - The Globe and Mail
Scholar Rock (NASDAQ:SRRK) Shares Gap UpWhat's Next? - MarketBeat
Transcript : Scholar Rock Holding CorporationSpecial Call - MarketScreener
Scholar Rock Stock Soars on Biopharma Firm's Weight-Loss Drug Trial Results - Yahoo Finance
Scholar Rock's Atrophy Drug When Combined With Eli Lilly's Zepbound Shows Around 55% Better Muscle Preservation In Weight Loss Study - Benzinga
Scholar Rock stock soars after drug shows promise in preserving lean mass during weight loss - Investing.com Australia
Trading Day Triumph: Scholar Rock Holding Corp (SRRK) Ends at 31.15, a -3.05 Surge/Plunge - DWinneX
Scholar Rock's drug helps Zepbound patients retain more muscle in trial - marketscreener.com
Scholar Rock (SRRK) Surges 14% Following EMBRAZE Trial Results | SRRK Stock News - GuruFocus
Scholar Rock (SRRK) Surges After Promising Weight Loss Trial - GuruFocus
Scholar Rock Reports Positive Results From Phase 2 EMBRAZE Study - Nasdaq
Scholar Rock stock gains on weight loss data (SRRK:NASDAQ) - Seeking Alpha
Scholar Rock (SRRK) Reveals Phase 2 Trial Success of Apitegromab with Tirzepatide | SRRK Stock News - GuruFocus
Scholar Rock's drug helps patients on Zepbound preserve muscle in trial - MarketScreener
Scholar Rock’s apitegromab preserves lean mass during weight loss - Investing.com
Scholar Rock's drug helps preserve lean mass in mid-stage trial - marketscreener.com
Scholar Rock's Breakthrough Drug Shows 55% Better Muscle Preservation in Weight Loss Study - Stock Titan
Notable Two Hundred Day Moving Average CrossSRRK - Nasdaq
Scholar Rock Holding Corp Executives Sell Shares to Cover Tax Obligations - TradingView
GAMMA Investing LLC Buys 30,140 Shares of Scholar Rock Holding Corporation (NASDAQ:SRRK) - MarketBeat
GAMMA Investing LLC Has $962,000 Stock Holdings in Scholar Rock Holding Co. (NASDAQ:SRRK) - Defense World
Rhumbline Advisers Purchases 7,491 Shares of Scholar Rock Holding Co. (NASDAQ:SRRK) - Defense World
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule - marketscreener.com
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Jefferies Names Akero Therapeutics, Scholar Rock As Biotech Companies With Takeover Potential, But Retail Isn’t Pleased By Stocktwits - Investing.com India
Scholar Rock at Goldman Sachs Conference: Strategic Focus on SMA By Investing.com - Investing.com Nigeria
Transcript : Scholar Rock Holding Corporation Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-11-2025 09 - MarketScreener
Truist Financial Sticks to Its Buy Rating for Nurix Therapeutics (NRIX) - The Globe and Mail
Scholar Rock Holding Co. (NASDAQ:SRRK) Stake Increased by California State Teachers Retirement System - MarketBeat
Scholar Rock (NASDAQ:SRRK) Trading Up 5.9%Here's What Happened - MarketBeat
Lifesci Capital Weighs in on Scholar Rock Q2 Earnings - MarketBeat
Scholar Rock (NASDAQ:SRRK) Upgraded at Lifesci Capital - MarketBeat
Exploring Three High Growth Tech Stocks In The US Market - Yahoo Finance
Mackenzie Financial Corp Invests $212,000 in Scholar Rock Holding Co. (NASDAQ:SRRK) - Defense World
Scholar Rock Holding Co. (NASDAQ:SRRK) Shares Purchased by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - MarketBeat
Analysts Set Expectations for Scholar Rock Q2 Earnings - Defense World
Scholar Rock Spotlights Revolutionary SMA Treatment at Goldman Sachs Healthcare Conference 2025 - Stock Titan
Squarepoint Ops LLC Takes $873,000 Position in Scholar Rock Holding Co. (NASDAQ:SRRK) - MarketBeat
Scholar Rock (NASDAQ:SRRK) Stock Rating Upgraded by Lifesci Capital - Defense World
Scholar Rock at Jefferies: Leadership Changes and Drug Launch Plans By Investing.com - Investing.com South Africa
Scholar Rock at Jefferies: Leadership Changes and Drug Launch Plans - Investing.com
Ameriprise Financial Inc. Has $813,000 Holdings in Scholar Rock Holding Co. (NASDAQ:SRRK) - Defense World
Scholar Rock Holding Co. (NASDAQ:SRRK) Insider Akshay Vaishnaw Sells 6,750 Shares - MarketBeat
Scholar Rock (NASDAQ:SRRK) Trading Down 6.2%Time to Sell? - MarketBeat
Scholar Rock appoints new Chief Brand Officer By Investing.com - Investing.com South Africa
Wellington Management Group LLP Buys 1,525,845 Shares of Scholar Rock Holding Co. (NASDAQ:SRRK) - MarketBeat
Scholar Rock Holding Co. (NASDAQ:SRRK) Director Jeffrey S. Flier Sells 6,075 Shares - MarketBeat
Insider Selling: Scholar Rock Holding Co. (NASDAQ:SRRK) Director Sells 5,400 Shares of Stock - MarketBeat
Regeneron's weight-loss drug helps patients on Wegovy preserve muscle - marketscreener.com
Scholar Rock appoints new Chief Brand Officer - Investing.com Australia
Scholar Rock Holding Corp Stock (SRRK) Financials Data
Revenue
Net Income
Cash Flow
EPS
Scholar Rock Holding Corp Stock (SRRK) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Qatanani Mo | CHIEF SCIENTIFIC OFFICER |
Jun 16 '25 |
Sale |
32.00 |
3,668 |
117,381 |
139,561 |
| Parlavecchio Caryn | CHRO |
Jun 16 '25 |
Sale |
32.00 |
6,186 |
197,961 |
157,642 |
| Ho Junlin | GENERAL COUNSEL |
Jun 16 '25 |
Sale |
32.00 |
7,442 |
238,154 |
222,569 |
1.13%
0.60%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):